Drug Profile

ACE 167

Alternative Names: ACE-167

Latest Information Update: 04 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Acesis BioMed
Developer Acesis BioMed; Unknown
Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
Mechanism of Action T lymphocyte stimulants; Testosterone congener stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Preclinical Hypogonadism
Research Cachexia; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes mellitus

28 Jul 2025 ACE 167 is available for licensing for Cachexia and Obesity as of 28 Jul 2025. https://acesisbio.com/
28 Jul 2025 Early research in Cachexia in USA (PO) (Acesis Biomed pipeline, July 2025)
28 Jul 2025 Early research in Non-alcoholic fatty liver disease in USA (PO) (Acesis Biomed pipeline, July 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com